Suraksha Diagnostic Limited , the largest integrated diagnostic chain in East India, has announced robust financial results for the first quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Highlights

The company reported a substantial increase in its consolidated revenue from operations, which rose to ₹725.86 crore in Q1 FY26, marking a 19.52% growth compared to the same quarter last year. This performance underscores Suraksha's strong market position and expanding operational footprint.

Profitability also saw a notable improvement:

• EBITDA reached ₹246.56 crore, up by 13.51% year-on-year
• Profit After Tax (PAT) stood at ₹91.75 crore, reflecting a 19.67% increase
• PAT margin improved to 12.64%, up from 12.62% in Q1 FY25

The company's earnings per share (EPS) for the quarter was ₹1.80, compared to ₹1.49 in the same period last year.

Operational Developments

Suraksha Diagnostic has made significant strides in expanding its service offerings and market presence:

1. Launch of Suraksha Genomics: The company introduced a new vertical dedicated to cutting-edge genetic and molecular testing services. This state-of-the-art facility offers comprehensive capabilities in prenatal diagnostics, inherited disorder identification, pharmacogenomics, and specialized oncology panels.

2. Strategic Acquisition: On April 9, 2025, Suraksha acquired a 63% stake in Fetomat Wellness Private Limited, a specialized healthcare provider focused on pregnancy care and related services. This acquisition is expected to create strong synergies with existing operations and unlock new growth opportunities in the healthcare segment.

3. Network Expansion: The company added three new centers during the quarter, strengthening its presence across various formats.

Management Commentary

Ms. Ritu Mittal, Joint Managing Director & CEO of Suraksha Diagnostic Limited, commented on the results: "We are pleased to report a strong performance for Q1 FY26, driven by consistent growth across our operations. Our strategic focus remains ambitious and future-ready. We are actively expanding into whole genome and metagenomic testing, while integrating AI-assisted variant interpretation to elevate diagnostic accuracy."

She further added, "As newer centres stabilize and begin contributing significantly, we expect to see a stronger and more profitable financial profile across our network. We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics."

Looking Ahead

With its strong financial performance, strategic expansions, and focus on cutting-edge diagnostic technologies, Suraksha Diagnostic Limited appears well-positioned for continued growth in the evolving healthcare landscape. The company's investments in genomics and strategic acquisitions are likely to play a crucial role in shaping its future trajectory in the diagnostic services sector.

Investors and stakeholders will be watching closely to see how these initiatives translate into sustained financial performance and market leadership in the coming quarters.

Suraksha Diagnostic , a prominent player in the diagnostic services sector, has made a strategic move to strengthen its market position. The company has successfully completed the acquisition of a controlling stake in Fetomat Wellness, marking a significant expansion in its healthcare portfolio.

Key Highlights of the Acquisition

• Suraksha Diagnostic has secured a 63.00% equity stake in Fetomat Wellness.
• Following this acquisition, Fetomat Wellness has become a subsidiary of Suraksha Diagnostic.

Strategic Implications

This acquisition represents a notable development for Suraksha Diagnostic, potentially expanding its service offerings and market reach. By bringing Fetomat Wellness under its umbrella, Suraksha Diagnostic is likely aiming to diversify its healthcare services and strengthen its position in the wellness sector.

About the Companies

Suraksha Diagnostic

Known for its diagnostic services, Suraksha Diagnostic has been expanding its footprint in the healthcare industry. This latest move indicates the company's strategy to grow through strategic acquisitions.

Fetomat Wellness

While specific details about Fetomat Wellness are not provided in the current update, the company's focus on wellness suggests a complementary addition to Suraksha Diagnostic's existing portfolio.

Industry Implications

The acquisition of Fetomat Wellness by Suraksha Diagnostic underscores the ongoing trend of consolidation and diversification in the healthcare sector. As companies seek to offer more comprehensive health and wellness solutions, such strategic moves are likely to shape the future landscape of the industry.

Investors and industry observers will be keen to see how this acquisition impacts Suraksha Diagnostic's market position and financial performance in the coming quarters.